Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4902141 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL4881908 | 0.88 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL4881911 | 0.88 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RECQLMAPTMEN1 | |
| SCHEMBL4901756 | 0.83 | L3MBTL1 (0.54) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4878430 | 0.83 | L3MBTL1 (0.54) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4878436 | 0.83 | L3MBTL1 (0.54) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4908928 | 0.83 | MAPT (0.48) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4908916 | 0.83 | MAPT (0.48) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4901749 | 0.83 | L3MBTL1 (0.54) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4927292 | 0.82 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227787-A1 | Use of New Lipoxygenase Inhibitors | BIOLIPOX AB (SE) | 2008-09-18 | — | — | US | disclosed |
| EP-1725227-A1 | USE OF NEW LIPOXYGENASE INHIBITORS | Biolipox AB (SE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005084656-A1 | USE OF NEW LIPOXYGENASE INHIBITORS | BIOLIPOX AB (SE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227787-A1 | Use of New Lipoxygenase Inhibitors | ALOX15, ALOX15B, ALOX12 | ALDH1A1 464/4885SMN1; SMN2 3659/4885RECQL 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.